Physicians' Academy for Cardiovascular Education

Lipids

HoFH: Why is early diagnosis important?

10' education - June 29, 2022 - Prof. Kausik Ray, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins

3' education - May 24, 2022 - Nicholas Marston, MD

Lipid management and the potential role of bempedoic acid

10' education - Apr. 26, 2022 - Rens Reeskamp, MD, PhD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD

Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies

3' education - Apr. 6, 2022 - Brian Bergmark, MD

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD - Online CME

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

HoFH: Why is early diagnosis important?

10' education - June 29, 2022 - Prof. Kausik Ray, MD
Homozygous familial hypercholesterolemia (HoFH) is a genetic condition that is associated with very high levels of LDL-c from birth. Prof. Ray shows how outcomes can be improved by earlier diagnosis and use of multiple lipid-lowering treatments.

Homozygous familial hypercholesterolemia (HoFH) is a genetic condition that is associated with very high levels of LDL-c from birth. Prof. Ray shows how outcomes can be improved by earlier diagnosis and use of multiple lipid-lowering treatments.

NICE publishes final draft guidance on icosapent ethyl

News - June 13, 2022

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD
GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

Very high HDL-c levels associated with higher mortality in patients with CAD

Literature - June 7, 2022 - Liu C, et al. - JAMA Cardiol. 2022

Historically, HDL-c is regarded as the ‘good’ cholesterol. But does this also apply to patients with coronary artery disease and very high HDL-c levels? In a recent analysis, this was examined using data from 2 large cohorts.

Lp(a) is not associated with thrombotic events

News - May 25, 2022

EAS 2022 A study found that Lp(a) is not associated with VTE and the increased risk of MI caused by high Lp(a) levels is unlikely to be decreased by antiplatelet or antithrombin therapy.

Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins

3' education - May 24, 2022 - Nicholas Marston, MD
An ASO targeting //ANGPTL3// mRNA, significantly reduced VLDL and remnant cholesterol, but had side effects at higher doses. What could be next steps in this research area?

EAS 2022 An ASO targeting ANGPTL3 mRNA, significantly reduced VLDL and remnant cholesterol, but had side effects at higher doses. What could be next steps in this research area?

Global registry reveals characteristics of HeFH in children and adolescents

News - May 24, 2022

EAS 2022 Data on characteristics of FH in children are critical to inform contemporary approaches to identify children/adolescents with FH worldwide.

Lipid management and the potential role of bempedoic acid

10' education - Apr. 26, 2022 - Rens Reeskamp, MD, PhD
Bempedoic acid has been approved by the FDA in 2020, but what is the potential place of bempedoic acid in the arsenal of lipid-lowering therapies?

Bempedoic acid has been approved by the FDA in 2020, but what is the potential place of bempedoic acid in the arsenal of lipid-lowering therapies? With question to test your knowledge.

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Combination of high Lp(a) and high BMI confers highest risk of calcific aortic valve disease

Literature - Apr. 20, 2022 - Kaltoft M et al. - J Am Coll Cardiol. 2022

The combination of high Lp(a) levels and high BMI conferred a 3.5-fold risk of CAVD compared with both risk factors in the bottom 50%. Absolute 10-year risk of CAVD was higher in men than in women and increased with higher age, Lp(a) and BMI.

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in  patients who are already being treated with statins.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.